New Vaccine could solve the problem of the costly Gilead’s Hepatitis C ‘Cure’

27/07/2016 - 3 minutes

Artes Biotechnology and Burnet Institute will join their proprietary technologies to develop a novel vaccine for the Hepatitis C virus. This could create a more affordable solution to reduce the high HCV-related mortality.

artes biotechnology hcv universal vaccineHepatitis C remains a health problem around the world. WHO estimates that more than half a million people die every year from consequences of HCV infection, such as liver cirrhosis or liver cancer.

Part of the solution could be the development of a prophylactic vaccine, which would protect healthy individuals and prevent re-infection in treated patients. Another important aspect is that it could reduce the economic burden of the disease – preventing disease is usually cheaper than treating it.

This is especially true for HVC, the cure of which (Gilead’s Sovaldi) is priced at around €100,000. Coupled with the high numbers of people infected, paying the therapy has been a challenge to health systems worldwide  – including in Europe.

Now,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member